 1987 Penguin edition | |
| Author | Allen Carr |
|---|---|
| Subject | Smoking |
| Pages | 239 |
| ISBN | 9780615482156 |
The Easy Way to Stop Smoking is a self-help book written by British author and accountant Allen Carr first published in 1985. The book aims to help people quit smoking, offering a range of different methods. Although championed by many celebrities, there has been limited empirical study of Carr's method. [1]
After 30 years of heavy smoking, Carr quit in 1983, at the age of 48. He subsequently left his job as an accountant in the same year and opened the first "easiest way" clinic, to help other addicts. Carr wrote a number of books intended to lead to smoking cessation and loss of excess weight, some of which were best sellers. [2]
Carr writes that smoking addiction is innately psychological and therefore this is the most significant factor in addiction to cigarettes. The book is divided into 44 chapters, whose purpose is to lead the smoker to, upon completion of reading the book, make the decision to quit smoking. [3]
A 2018 study funded by DOH Ireland set out with an objective to determine if Allen Carr's Easyway to Stop Smoking was superior to Quit.ie in a randomised clinical trial. Quit.ie is an online portal for smoking cessation. The Allen Carr method was implemented in group sessions. The trial consisted of 300 adults and concluded that Allen Carr's method was superior to Quit.ie. This was the first clinical trial of Carr's method. The reseach found "All AC quit rates were superior to Quit.ie, outcomes were comparable with established interventions." [1]
Pneumologist and tobacco addiction expert Bertrand Dautzenberg does not consider Allen Carr's Easyway to deal with evidence-based techniques. Dautzenberg's opinion is that while coaching methods are acceptable, Carr's book dismisses nicotine physical dependence and opposes substitution treatment; he concludes that doctors should advise against Allen Carr's Easyway method. Dautzenberg's own critics have noted that Dautzenberg's daily practice and interest is in the study of addiction and not in possible cures for addiction. [4]
www.medcom.fr Le Pr Bertrand Dautzenberg est pneumologue, responsable de l'unité tabac de la Pitié-Salpêtrière à Paris. Il travaille depuis plus de 35 ans dans le contrôle du tabac, a écrit 7 livres sur différents aspects du tabagisme. Il est très actif auprès de nombreuses organisations de contrôle du tabagisme aussi bien au niveau français qu'européen.
 | This article about a self-help book is a stub. You can help Wikipedia by expanding it. |
Smoking cessation, usually called quitting smoking or stopping smoking, is the process of discontinuing tobacco smoking. Tobacco smoke contains nicotine, which is addictive and can cause dependence. As a result, nicotine withdrawal often makes the process of quitting difficult.
"Cold turkey" refers to the abrupt cessation of a substance dependence and the resulting unpleasant experience, as opposed to gradually easing the process through reduction over time or by using replacement medication.
Allen John Carr was a British author of books about stopping smoking and other psychological dependencies including alcohol addiction.
Nicorette is the brand name of a number of products for nicotine replacement therapy (NRT) that contain nicotine polacrilex. Developed in the late 1970s in Sweden by AB Leo in the form of a chewing gum, Nicorette was the first nicotine replacement product on the market.
Nicotine marketing is the marketing of nicotine-containing products or use. Traditionally, the tobacco industry markets cigarette smoking, but it is increasingly marketing other products, such as electronic cigarettes and heated tobacco products. Products are marketed through social media, stealth marketing, mass media, and sponsorship. Expenditures on nicotine marketing are in the tens of billions a year; in the US alone, spending was over US$1 million per hour in 2016; in 2003, per-capita marketing spending was $290 per adult smoker, or $45 per inhabitant. Nicotine marketing is increasingly regulated; some forms of nicotine advertising are banned in many countries. The World Health Organization recommends a complete tobacco advertising ban.
Smokeless tobacco is a tobacco product that is used by means other than smoking. Their use involves chewing, sniffing, or placing the product between gum and the cheek or lip. Smokeless tobacco products are produced in various forms, such as chewing tobacco, snuff, snus, and dissolvable tobacco products. Smokeless tobacco products typically contain over 3000 constituents. Smokeless tobacco is widely used in South Asia and this accounts for about 80% of global consumption, as per WHO data All smokeless tobacco products contain nicotine and are therefore highly addictive. Quitting smokeless tobacco use is as challenging as smoking cessation.
NicVAX is an experimental conjugate vaccine intended to reduce or eliminate physical dependence to nicotine. According to the U.S. National Institute of Drug Abuse, NicVAX can potentially be used to inoculate against nicotine addiction. This proprietary vaccine is being developed by Nabi Biopharmaceuticals of Rockville, MD. with the support from the U.S. National Institute on Drug Abuse. NicVAX consists of the hapten 3'-aminomethylnicotine which has been conjugated (attached) to Pseudomonas aeruginosa exotoxin A.
Nicotine withdrawal is a group of symptoms that occur in the first few weeks after stopping or decreasing use of nicotine. Symptoms include intense cravings for nicotine, anger or irritability, anxiety, depression, impatience, trouble sleeping, restlessness, hunger or weight gain, and difficulty concentrating. Withdrawal symptoms make it harder to quit nicotine products, and most methods for quitting smoking involve reducing nicotine withdrawal. Quit smoking programs can make it easier to quit. Nicotine withdrawal is recognized in both the American Psychiatric Association Diagnostic and Statistical Manual and the WHO International Classification of Diseases.
Tobacco harm reduction (THR) is a public health strategy to lower the health risks to individuals and wider society associated with using tobacco products. It is an example of the concept of harm reduction, a strategy for dealing with the use of drugs. Tobacco smoking is widely acknowledged as a leading cause of illness and death, and reducing smoking is vital to public health.
Nicotine dependence is a state of dependence upon nicotine. Nicotine dependence is a chronic, relapsing disease defined as a compulsive craving to use the drug, despite social consequences, loss of control over drug intake, and emergence of withdrawal symptoms. Tolerance is another component of drug dependence. Nicotine dependence develops over time as a person continues to use nicotine. The most commonly used tobacco product is cigarettes, but all forms of tobacco use and e-cigarette use can cause dependence. Nicotine dependence is a serious public health problem because it leads to continued tobacco use, which is one of the leading preventable causes of death worldwide, causing more than 8 million deaths per year.
Nicotine Anonymous (NicA) is a twelve-step program founded in 1982 for people desiring to quit smoking and live free of nicotine. As of July 2017, there are over 700 face-to-face meetings in 32 countries worldwide with the majority of these meetings occurring in the United States, Iran, India, Canada, Brazil, the United Kingdom, Australia, Russia and in various online community and social media platforms.. NicA maintains that total abstinence from nicotine is necessary for recovery. NicA defines abstinence as “a state that begins when all use of nicotine ceases.
Elbert D. Glover is an American researcher and author in the field of tobacco addiction and smoking cessation. After several academic positions, he retired as professor emeritus at the University of Maryland at College Park School of Public Health where he served as Chairperson of the Department of Behavioral and Community Health from 2005 to his retirement in 2015. Moreover, he was entrepreneur, editor, publisher, co-founder and principal owner of Health Behavior and Policy Review, and co-founder, owner, editor, and publisher of American Journal of Health Behavior and Tobacco Regulatory Science. Glover was the founder of the American Academy of Health Behavior and served as its first president from 1997 to 2001.
TA-NIC is a proprietary vaccine in development similar to TA-CD but being used to create human anti-nicotine antibodies in a person to destroy nicotine in the human body so that it is no longer effective.
Joel Spitzer is an American smoking cessation educator. He currently serves as technical advisor at WhyQuit.com, a free nicotine dependence recovery website. All of his videos and writings on WhyQuit.com end with his advice, "Never Take Another Puff!"
The scientific community in the United States and Europe are primarily concerned with the possible effect of electronic cigarette use on public health. There is concern among public health experts that e-cigarettes could renormalize smoking, weaken measures to control tobacco, and serve as a gateway for smoking among youth. The public health community is divided over whether to support e-cigarettes, because their safety and efficacy for quitting smoking is unclear. Many in the public health community acknowledge the potential for their quitting smoking and decreasing harm benefits, but there remains a concern over their long-term safety and potential for a new era of users to get addicted to nicotine and then tobacco. There is concern among tobacco control academics and advocates that prevalent universal vaping "will bring its own distinct but as yet unknown health risks in the same way tobacco smoking did, as a result of chronic exposure", among other things.
Jed Eugene Rose is an American academic professor, inventor and researcher in the field of nicotine and smoking cessation. Rose is presently the President and CEO of the Rose Research Center, LLC in Raleigh, North Carolina. Additionally, he is the Director of the Duke Center for Smoking Cessation at Duke University Medical Center.
A heated tobacco product (HTP) is a tobacco product that heats the tobacco at a lower temperature than conventional cigarettes. These products contain nicotine, which is a highly addictive chemical. The heat generates an aerosol or smoke to be inhaled from the tobacco, which contains nicotine and other chemicals. HTPs may also contain additives not found in tobacco, including flavoring chemicals. HTPs generally heat tobacco to temperatures under 600 °C (1100 °F), a lower temperature than conventional cigarettes.
Marewa Glover is a New Zealand public health academic specialising in smoking cessation. She has worked at the University of Auckland and been a full professor at Massey University. She set up the Centre for Research Excellence: Indigenous Sovereignty and Smoking (COREISS) in 2018.
Iqos is a line of heated tobacco and electronic cigarette products manufactured by Philip Morris International (PMI). It was first introduced in November 2014 in Japan and Italy. Most of the IQOS products are devices that heat tobacco without burning it.
The composition of the emissions generated from heated tobacco products are generally lower than that found in cigarette smoke. This is due to the comparatively low temperatures, the filter systems, and physical design. The composition of what is produced is complex. The main toxicants found in the emissions of cigarette smoke are also found in the emissions of these products in varying concentrations. The aerosol generated contains levels of nicotine and cancer-causing chemicals that are comparable to regular cigarettes. The emissions contained 84% of the nicotine found in regular cigarettes.